AI in oncology market to reach US$ 22.85 Billion by 2033, growing at a CAGR of 25.3%, Brest Cancer segment holds 28.23% Market Revenue, North America led 40% share of Global Market

The global AI in oncology market size reached US$ 2.43 Billion in 2024 and is expected to reach US$ 22.85 Billion by 2033, growing at a CAGR of 25.3% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/ai-in-oncology-market?pratik

The global AI in oncology market is witnessing rapid growth, fueled by advancements in artificial intelligence technologies, increased cancer prevalence, and a rising emphasis on personalized medicine. Pharmaceutical and healthcare companies invest heavily in AI-driven diagnostic tools, treatment planning systems, and drug discovery platforms. Regulatory bodies also support this shift, with approvals for AI-based cancer detection devices becoming more common.

United States: Key Industry Developments
✅ November 2025: Predictive Oncology Inc. expanded its AI-driven platform to include biomarker discovery and drug repurposing, using its live-cell tumor biobank to accelerate precision oncology innovation.​

✅ June 2025: FDA granted De Novo authorization to the Clairity Breast platform for five-year breast-cancer risk prediction, enhancing early detection capabilities.​

✅ May 2025: Pathos AI raised USD 365 million in Series D financing at a USD 1.6 billion valuation to scale data-driven oncology drug discovery efforts.

✅ June 2025: Viz.ai announced a strategic collaboration with Novartis to develop AI-powered workflows for breast and prostate cancer diagnostics and treatment planning promising faster diagnosis and more precise care, especially for underserved patients.

✅ April 2025: iCAD integrated its "ProFound AI Breast Health Suite" into Microsoft Precision Imaging Network marking a significant push in AI-driven mammography and imaging diagnostics for cancer in the U.S. and allied markets.

Germany: Key Industry Developments
✅ November 2025: ESMO (European Society for Medical Oncology) launched its first-ever "Congress on Artificial Intelligence and Digital Oncology (AI&DO)" in Berlin (14 November 2025), signalling a major institutional push to integrate AI systematically into European cancer care and shape standards for clinical AI deployment.

✅ June 2025: Technical University of Munich (TUM) and its hospital received funding from Google.org to develop "AIdvice Assistant," an AI-powered chatbot designed to deliver understandable, evidence-based oncology treatment guidance to patients and clinicians improving accessibility and patient education in cancer care.

✅ 2025 (ongoing R&D): A German university (as part of the 2025 EIC Pathfinder Challenge) issued a call for consortia to build generative-AI based agents for cancer diagnosis and treatment aiming to develop next-gen AI agents capable of multimodal diagnostics and personalized oncology decision-support across Europe.

Recent Merges & acquisition
→ In 2025 Q2, Tempus AI acquired Paige, gaining access to 7 million pathology slides and FDA-cleared tools. This acquisition positions Tempus as a dominant player in the AI-driven oncology market projected to reach $10 billion by 2030. The deal was stock-based, preserving cash, and strategically complemented Tempus's AI drug discovery collaborations.​

→ In 2025 Q2, Teladoc Health acquired UpLift, a virtual mental health provider, for $45 million cash plus earnouts. This expanded Teladoc's capabilities in digital health and therapy, reflecting broader AI and healthcare tech consolidation trends.​

→ In 2025 Q3, Carlyle Group acquired Psychiatric Medical Care in a private equity-backed deal valued at approximately 20x EBITDA. Though behavioral health focused, this acquisition reflects broader investment activity within healthcare AI and digital health markets in 2025.

Why Purchase the Report?
→ To visualize the global gummy supplements market segmentation based on type, end-user, distribution channel, and region as well as understand key commercial assets and players.
→ Identify commercial opportunities by analyzing trends and co-development.
→ Excel data sheet with numerous data points of gummy supplements market-level with all segments.
→ PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
→ Product mapping available as Excel consisting of key products of all the major players.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=ai-in-oncology-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Market Segmenatation-

Segmentation by Cancer Type
→ Breast Cancer: This segment leverages AI for early detection through image analysis of mammograms and risk prediction models, aiding in personalized screening and diagnosis. It holds the largest market share at approximately 28.23% in recent data, driven by high prevalence and advanced AI tools for tumor characterization.​

→ Lung Cancer: AI applications here focus on CT scan analysis for nodule detection, staging, and predicting treatment responses, accelerating pathology reviews. This segment is the fastest-growing, fueled by rising incidence and AI's role in precise radiotherapy planning.​

→ Prostate Cancer: Involves AI for MRI interpretation, biopsy guidance, and genomic profiling to identify aggressive tumors early. It captures a notable share alongside breast and lung cancers, supported by demand for precision diagnostics.​

→ Colorectal Cancer: AI enhances endoscopy image analysis for polyp detection and molecular subtyping to guide therapy selection. This segment contributes steadily, benefiting from AI in screening programs and outcome prediction.​

→ Brain Tumor: AI assists in MRI segmentation for tumor delineation and surgical planning, addressing complex imaging challenges. It represents a growing portion, particularly for under-served tumor types with emerging applications.​

→ Other Cancer Types: Encompasses rarer cancers like kidney or solid malignancies, where AI supports small-data techniques for drug optimization and prognosis. Collectively, these hold the remaining share, with solid malignancies dominating overall.​

Segmentation by Treatment Type
→ Radiotherapy: Dominates with automated contouring, dose planning, and motion tracking, reducing preparation time significantly. It secured about 41.45% market share in 2024, extending into 2025 due to workflow efficiencies.​

→ Immunotherapy: Focuses on biomarker selection, toxicity prediction for checkpoint inhibitors, and CAR-T therapies. Projected at a high CAGR of 37.76% through 2030, reflecting surging demand for personalized immune responses.​

→ Chemotherapy: AI optimizes dosing, response monitoring, and side effect prediction via patient data analytics. It forms a core segment, integrated with multi-modal treatment planning.

Regional insights:-
→ North America - 40.0%
North America is the dominant region, led by the U.S. because of advanced healthcare infrastructure, high R&D and VC funding, widespread clinical AI pilots, extensive imaging data availability, and favorable reimbursement/regulatory activity for AI tools. This concentration of talent, capital, and pilot programs drives the largest regional market share.

→ Europe (Western & Central) - 28.0%
Europe holds the second largest share thanks to strong oncology research centers, government and EU initiatives for digital health, growing adoption in major markets (Germany, UK, France), and an expanding regulatory pathway for clinical-grade AI solutions. Pan-European collaborations are accelerating clinical validation and deployment.

→ Asia-Pacific - 22.0%
APAC is the fastest-growing region, driven by China, Japan, South Korea, India and Australia investing in AI, rapidly expanding imaging capacity, and large unmet needs in cancer screening and diagnostics. Low-cost scale manufacturing and public-private partnerships are accelerating deployments across hospitals and networks. Precedence

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/ai-in-oncology-market?pratik

Competitive Landscape:-
→ The top companies in the AI in oncology market include Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagene AI Ltd., Predictive Oncology, Tempus, among others.

Key Developments:-
→ In February 2025, Avitia announced its business launch and $5M seed investment from PacBridge Capital Partners ("PacBridge"). With Avitia's platform, laboratories and clinicians now have access to advanced molecular testing directly on-site. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster, all at reduced costs compared to existing send-out alternatives.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.